| Literature DB >> 32414138 |
Anna Sadowska1, Ewa Zapora2, Diana Sawicka1, Katarzyna Niemirowicz-Laskowska1, Arkadiusz Surażyński3, Katarzyna Sułkowska-Ziaja4, Katarzyna Kała4, Marcin Stocki2, Marek Wołkowycki2, Sławomir Bakier2, Anna Pawlik5, Magdalena Jaszek5, Bożena Muszyńska4, Halina Car1.
Abstract
Application of substances from medicinal mushrooms is one of the interesting approaches to improve cancer therapy. In this study, we commenced a new attempt in the field of Heterobasidion annosum (Fr.) Bref. sensu lato to further extend our knowledge on this basidiomycete fungus. For this purpose, analysis of the active substances of Heterobasidion annosum methanolic extract and also its influence on colorectal cancer in terms of in vitro and in vivo experiments were performed. In vivo studies on mice were conducted to verify its acute toxicity and to further affirm its anticancer potential. Results indicated that all the most common substances of best known medicinal mushrooms that are also responsible for their biological activity are present in tested extracts. In vitro tests showed a high hemocompatibility and a significant decrease in viability and proliferation of DLD-1 cells in a concentration-dependent manner of Heterobasidion annosum extract. The studies performed on xenograft model of mice showed lower tendency of tumor growth in the group of mice receiving Heterobasidion annosum extract as well as mild or moderate toxicity. Obtained results suggest beneficial potential of Heterobasidion annosum against colon cancer as cytotoxic agent or as adjuvant anticancer therapy.Entities:
Keywords: Heterobasidion annosum; active substances; apoptosis; colon cancer; mouse model; toxicity
Mesh:
Substances:
Year: 2020 PMID: 32414138 PMCID: PMC7279362 DOI: 10.3390/ijms21103447
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1FTIR spectra of Heterobasidion annosum extract.
Content of selected organic compounds and bioelements in Heterebasidion annosum fruiting bodies based on the results from GC-MS, HPLC, and F-atomic absorption spectroscopy (AAS) analysis. TIC–total ion current; d.w.–dry weight
|
|
|
| Total carbohydrates | 6.82 |
| Total sterols | 1.82 |
| Total carboxylic acid | 1.74 |
|
|
|
| 5-Hydroxy-L-tryptophan | 39.1 ± 1.4 |
| L-Tryptophan | 34.9 ± 2.4 |
| 6-Methyl-D,L-tryptophan | 1.1 ± 0.2 |
| Melatonin | * |
|
|
|
| Protocatechuic acid | 2.2 ± 0,05 |
| Gentisic acid | 76.5 ± 0.7 |
|
|
|
| Ergosterol | 9.5 ± 0.07 |
| Ergosterol peroxide | 23.8 ± 0.3 |
|
|
|
| Cu | 1.0 ± 0.06 |
| Fe | 14.2 ± 1.7 |
| Zn | 4.2 ± 0.3 |
| Mg | 186.6 ± 4.5 |
* less than 0.001 mg/100 g dry weight of extract; n = 3.
Figure 2Hemocompatibility and cytotoxicity of Heterobasidion annosum (HA) extract against DLD-1 cells. Panel A shows high compatibility of HA extract against representative of host cells–RBC cells. The ability to decrease viability (panel B) and proliferation (panel C) of DLD-1 colorectal cancer cells after treatment with HA extract at different concentration range 0.1–5 µg/mL. Pleiotropic mode of action of HA extract—reduction of metabolic activity (D), increasing number of depolarized cells (E), and leakage of LDH from the treated cells (F). The distribution of thiol levels in DLD-1 cells after treatment by HA extract- fluorescence intensity scatters (G-control, H-0.1 µg/mL and I-1 µg/mL) and column plot (J). PI—propidium iodide, VB-48—VitaBright-48 iodide; Statistical significance: (pH = 7.4) vs. (pH = 6.8) a p < 0.01; (pH = 6.8) vs. (pH = 6.2) b p < 0.01; (pH = 6.8) vs. (pH = 5.4) c p < 0.01 (panel A); * p < 0.05 vs. control, ** p < 0.01 vs. control; *** p < 0.001 vs. control.
Figure 3The cytoplasmatic and nucleus level of caspase-3, NF-κB, and p53 in DLD-1 cell line after HA extract application. Panels (A–D) show expression of caspase 3 after treatment of DLD-1 by different concentrations of HA extract (0.1–5 µg/mL). Increasing expression of NF-κB and p53 protein after addition of HA extract at different concentration range 0.1–5 µg/mL are showed at panels (E–H) and (I–L), respectively. Magnification 400×, Scale bar = 20 μm.
Figure 4Analysis of tumor volume (panel A) and tumor mass (panel B) changes in study groups (control–DLD-1, HA-1 mg/kg body weight, DLD-1+5-FU); example images of tumors (C), scale bar = 0.5 cm * p < 0.05 vs. control.
Figure 5Histological images of stomach (A–C) and intestine (D–F) showing no pathological changes in animal receiving the highest doses of HA extract in acute toxicity study. Magnification 100×.